ONE STOP SYSTEMS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ONE STOP SYSTEMS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $37.03M | Mar 21, 2019 |
| FY2018 | Dec 31, 2017 | $27.54M | Mar 21, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.22M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $24.56M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $60.90M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $72.42M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $61.98M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $51.90M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $58.31M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $37.03M | Mar 26, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.98M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $622.9K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $17.95M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $20.40M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $19.64M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $16.43M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $19.40M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $11.33M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.66M | Mar 21, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.09M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($13.63M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($6.72M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($2.23M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.33M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.5K) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($900.3K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.14M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $96.6K | Mar 21, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.38M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($15.66M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($7.92M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.57M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.75M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($424.3K) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($779.0K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.18M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($450.4K) | Mar 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.44M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.47M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.33M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.74M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.03M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.32M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $4.84M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.00M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.69M | Mar 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.36M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $7.20M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $9.26M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $7.28M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $7.66M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $8.42M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $8.50M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $6.51M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.50M | Mar 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($108.1K) | Mar 19, 2025 |
| FY2024 | Dec 31, 2023 | ($439.7K) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($7.81M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.62M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($250.2K) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.37M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.89M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($381.8K) | Mar 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.6K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $228.3K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $821.8K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $529.9K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $563.8K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $820.3K | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.39M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $623.2K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $425.5K | Mar 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.82M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $36.93M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $48.27M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $56.36M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $51.59M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $39.13M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $39.78M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $36.06M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $16.92M | Mar 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.82M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $9.76M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $8.68M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $12.04M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $9.63M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.84M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $11.01M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.48M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.30M | Mar 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.49M | Mar 19, 2025 |
| FY2024 | Dec 31, 2023 | $1.49M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $7.12M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $7.12M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.12M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $7.12M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.91M | Mar 26, 2020 |
| FY2018 | Oct 31, 2018 | $1.49M | Mar 21, 2019 |
| FY2018 | Dec 31, 2017 | $3.32M | Mar 21, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.97M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($22.05M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($8.42M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.70M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $571.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($1.76M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($1.76M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($854.9K) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $281.4K | Mar 21, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.17M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $4.04M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.05M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $3.11M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.10M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $6.32M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $5.19M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.27M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $185.7K | Mar 21, 2019 |
| FY2018 | Dec 31, 2016 | $14.2K | Mar 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.36M | Mar 23, 2023 |
| FY2021 | Dec 31, 2021 | $3.73M | Mar 24, 2022 |
| FY2020 | Dec 31, 2020 | $5.66M | Mar 25, 2021 |
| FY2019 | Dec 31, 2019 | $2.33M | Mar 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 21, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 21, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.58M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 21.15M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 20.66M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 20.08M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 18.77M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 16.68M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 16.12M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 14.22M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 5.51M | Mar 21, 2019 |